Trial Profile
A retropsective,cohort study assessing incidence of venous thromboembolism and its associated risk factors in patients with Multiple Myeloma treated with Immunomodulatory agents(Thalidomide,Lenalidomide,Pomalidomide)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jan 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Pomalidomide (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 11 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.